Gregory Renza
Stock Analyst at Truist Securities
(4.19)
# 481
Out of 5,102 analysts
239
Total ratings
45.63%
Success rate
17.14%
Average return
Main Sectors:
Stocks Rated by Gregory Renza
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| REGN Regeneron Pharmaceuticals | Assumes: Buy | $812 → $798 | $737.93 | +8.14% | 1 | Nov 24, 2025 | |
| CATX Perspective Therapeutics | Assumes: Buy | $8 → $12 | $2.64 | +355.41% | 7 | Nov 24, 2025 | |
| NRIX Nurix Therapeutics | Assumes: Buy | $23 → $30 | $19.42 | +54.48% | 12 | Nov 24, 2025 | |
| GILD Gilead Sciences | Assumes: Buy | $145 → $140 | $123.15 | +13.68% | 1 | Nov 24, 2025 | |
| AMGN Amgen | Assumes: Hold | $298 → $318 | $317.03 | +0.31% | 18 | Nov 24, 2025 | |
| XNCR Xencor | Initiates: Buy | $29 | $17.38 | +66.86% | 10 | Nov 24, 2025 | |
| VRDN Viridian Therapeutics | Initiates: Buy | $41 | $32.60 | +25.77% | 12 | Nov 24, 2025 | |
| NUVB Nuvation Bio | Initiates: Buy | $11 | $8.29 | +32.77% | 7 | Nov 24, 2025 | |
| NUVL Nuvalent | Initiates: Buy | $140 | $107.12 | +30.69% | 1 | Nov 24, 2025 | |
| MNKD MannKind | Initiates: Buy | $9 | $5.82 | +54.77% | 2 | Nov 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $59 | $33.56 | +75.80% | 13 | Nov 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $14 | $12.95 | +8.11% | 4 | Nov 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $62 | $41.63 | +48.93% | 4 | Nov 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Hold | $10 | $7.38 | +35.50% | 4 | Nov 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $400 | $322.73 | +23.94% | 3 | Nov 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $51 | $30.31 | +68.26% | 1 | Nov 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $32 | $27.65 | +15.73% | 7 | Nov 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $140 | $130.40 | +7.36% | 1 | Nov 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $31 → $35 | $220.19 | -84.10% | 3 | May 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $26 | $26.77 | -2.88% | 16 | May 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $8 | $4.01 | +99.50% | 12 | May 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Sector Perform | $5 | $2.15 | +133.10% | 11 | May 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $40 | $41.58 | -3.80% | 10 | May 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $182 → $172 | $166.19 | +3.50% | 14 | May 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Perform | $113 → $38 | $86.78 | -56.78% | 14 | Apr 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $12 | $11.69 | +2.65% | 6 | Mar 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $16 → $14 | $9.65 | +45.08% | 10 | Mar 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Sector Perform | $18 | $26.01 | -30.80% | 11 | Jan 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $68 → $48 | $1.84 | +2,515.80% | 4 | Jan 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sector Perform | $110 → $20 | $8.32 | +140.38% | 7 | Nov 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $16 | $0.79 | +1,927.11% | 1 | Aug 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sector Perform | $2,160 → $180 | $20.19 | +791.53% | 4 | Jun 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Perform | $100 → $80 | $0.95 | +8,290.82% | 5 | Mar 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sector Perform | $105 → $30 | $0.48 | +6,134.41% | 3 | Jun 2, 2020 |
Regeneron Pharmaceuticals
Nov 24, 2025
Assumes: Buy
Price Target: $812 → $798
Current: $737.93
Upside: +8.14%
Perspective Therapeutics
Nov 24, 2025
Assumes: Buy
Price Target: $8 → $12
Current: $2.64
Upside: +355.41%
Nurix Therapeutics
Nov 24, 2025
Assumes: Buy
Price Target: $23 → $30
Current: $19.42
Upside: +54.48%
Gilead Sciences
Nov 24, 2025
Assumes: Buy
Price Target: $145 → $140
Current: $123.15
Upside: +13.68%
Amgen
Nov 24, 2025
Assumes: Hold
Price Target: $298 → $318
Current: $317.03
Upside: +0.31%
Xencor
Nov 24, 2025
Initiates: Buy
Price Target: $29
Current: $17.38
Upside: +66.86%
Viridian Therapeutics
Nov 24, 2025
Initiates: Buy
Price Target: $41
Current: $32.60
Upside: +25.77%
Nuvation Bio
Nov 24, 2025
Initiates: Buy
Price Target: $11
Current: $8.29
Upside: +32.77%
Nuvalent
Nov 24, 2025
Initiates: Buy
Price Target: $140
Current: $107.12
Upside: +30.69%
MannKind
Nov 24, 2025
Initiates: Buy
Price Target: $9
Current: $5.82
Upside: +54.77%
Nov 24, 2025
Initiates: Buy
Price Target: $59
Current: $33.56
Upside: +75.80%
Nov 24, 2025
Initiates: Buy
Price Target: $14
Current: $12.95
Upside: +8.11%
Nov 24, 2025
Initiates: Buy
Price Target: $62
Current: $41.63
Upside: +48.93%
Nov 24, 2025
Initiates: Hold
Price Target: $10
Current: $7.38
Upside: +35.50%
Nov 24, 2025
Initiates: Buy
Price Target: $400
Current: $322.73
Upside: +23.94%
Nov 24, 2025
Initiates: Buy
Price Target: $51
Current: $30.31
Upside: +68.26%
Nov 24, 2025
Initiates: Buy
Price Target: $32
Current: $27.65
Upside: +15.73%
Nov 24, 2025
Initiates: Buy
Price Target: $140
Current: $130.40
Upside: +7.36%
May 23, 2025
Maintains: Outperform
Price Target: $31 → $35
Current: $220.19
Upside: -84.10%
May 19, 2025
Reiterates: Outperform
Price Target: $26
Current: $26.77
Upside: -2.88%
May 15, 2025
Reiterates: Outperform
Price Target: $8
Current: $4.01
Upside: +99.50%
May 14, 2025
Reiterates: Sector Perform
Price Target: $5
Current: $2.15
Upside: +133.10%
May 14, 2025
Reiterates: Outperform
Price Target: $40
Current: $41.58
Upside: -3.80%
May 7, 2025
Maintains: Outperform
Price Target: $182 → $172
Current: $166.19
Upside: +3.50%
Apr 16, 2025
Maintains: Sector Perform
Price Target: $113 → $38
Current: $86.78
Upside: -56.78%
Mar 26, 2025
Reiterates: Outperform
Price Target: $12
Current: $11.69
Upside: +2.65%
Mar 21, 2025
Maintains: Outperform
Price Target: $16 → $14
Current: $9.65
Upside: +45.08%
Jan 14, 2025
Reiterates: Sector Perform
Price Target: $18
Current: $26.01
Upside: -30.80%
Jan 9, 2025
Maintains: Outperform
Price Target: $68 → $48
Current: $1.84
Upside: +2,515.80%
Nov 5, 2024
Downgrades: Sector Perform
Price Target: $110 → $20
Current: $8.32
Upside: +140.38%
Aug 14, 2024
Reiterates: Outperform
Price Target: $16
Current: $0.79
Upside: +1,927.11%
Jun 27, 2023
Downgrades: Sector Perform
Price Target: $2,160 → $180
Current: $20.19
Upside: +791.53%
Mar 16, 2022
Maintains: Sector Perform
Price Target: $100 → $80
Current: $0.95
Upside: +8,290.82%
Jun 2, 2020
Downgrades: Sector Perform
Price Target: $105 → $30
Current: $0.48
Upside: +6,134.41%